Accordingly, the inhibition of inflammation promoting cancer is anticipated by targeting key mediators and/or regulatory factors (such as NF‐κB and STAT3) of inflammatory pathways and cytokines (e.g., IL‐1, TNF, and IL‐6). This evidence concerns the gene STAT3 and cancer.